PyInvesting

Market research

CAPLIPOINT.NSE Caplin Point Laboratories Limited

NSE INR Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
190B
P/E ratio
29.32
Analyst target
2765
Dividend yield
0.0%
Beta
0.37

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 5 months ago

Caplin Point Laboratories Limited is currently in a long term uptrend where the price is trading 29.7% above its 200 day moving average.

From a valuation standpoint, the stock is 26.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.

Caplin Point Laboratories Limited's total revenue rose by 20.2% to $3B since the same quarter in the previous year.

Its net income has increased by 10.1% to $645M since the same quarter in the previous year.

Finally, its free cash flow grew by 286.9% to $2B since the same quarter in the previous year.

Based on the above factors, Caplin Point Laboratories Limited gets an overall score of 5/5.